

A Reply to the Letter in Response to the Article “Seroprevalence of Hepatitis B Virus, Hepatitis C Virus, Syphilis, and Associated Factors Among Female Sex Workers in Gondar Town, Northwest Ethiopia” [Response to Letter]

Mitikie Wondmagegn^{1,*}, Yitayih Wondimeneh², Alem Getaneh², Getnet Ayalew^{2,*}

¹Department of Medical Laboratory Science, College of Medicine and Health Sciences, Debre Tabor University, Debre Tabor, Ethiopia; ²Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

*These authors contributed equally to this work

Correspondence: Getnet Ayalew, Department of Medical Microbiology, School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, P.O.Box 196, Gondar, Ethiopia, Tel +251-918-73-00-13, Email aget2289@gmail.com

Dear editor

We have read and appreciated the response letter by Isnawati et al to our article entitled “Seroprevalence of Hepatitis B Virus, Hepatitis C Virus, Syphilis, and Associated Factors Among Female Sex Workers in Gondar Town, Northwest Ethiopia.”

The letter really points out some important issues; we thank you for that, but we also want to respond to some of the issues. The first point that was raised on the issue of screening simultaneously both HBsAg and HBsAb, as it is recommended, was that screening only HBsAg is not adequate from two points of view.

The first is the issue of infection type: whether acute, chronic, or in recovery (viral clearance) from another HBV serotype, “HBsAg examination without being followed by other serological tests (HbsAb and HBcAb) could not distinguish the type of infection”. It is useful to have information about the type of infection; however, our goal was to determine whether or not the female sex workers (FSWs) had the infection.

The recommended test could not distinguish the chronicity of the HBV infection; possibly, the Hepatitis B core antibody (HBcAb) could tell of a previous HBV infection, but this would not mean that it was a chronic infection. To confirm chronic infection, we must repeat the HBsAg test after 6 months.^{1,2} Screening for HBsAg can detect current infection. This was the primary goal of the research. Hepatitis B surface antibody (HbsAb) serological test: The presence of anti-HBs is commonly interpreted as indicating recovery and immunity from hepatitis B virus infection or successful vaccination against hepatitis B virus.^{1,2} The presence or absence of HbsAb does not indicate whether the individual has acute or chronic HBV infection.^{1,2}

The second issue here is that,

put alongside the results of the HBsAg test with anti-HCV and syphilis antibody data is not appropriate. Anti-HCV and anti-Syphilis showed that the respondent had been in contact with microorganisms, whether exposure or infection could not be ascertained. Both only provide evidence of developed immunity as a result of past natural infection, post-vaccination or even development of immunity that occurs concurrently with the disease. (acute or chronic)

The main thing the authors missed is that there is no protective vaccine against the hepatitis C virus (HCV). That is why in resource-limited countries like Ethiopia, screening for HCV infection is done by testing for the presence or absence of anti-HCV. Although a positive anti-HCV antibody test cannot differentiate between acute and chronic HCV infection, it may indicate infection.^{3,4} Post-vaccination screening is mandatory for HBV infection since there is a vaccine for HBV infection prevention.

In our study, we found no FSW with a history of HBV vaccination. By 2007, Ethiopia had implemented universal routine HBV vaccination through the Expanded Program for Immunization (EPI).⁵ As a result, the FSWs in the study could not be vaccinated through the EPI program. This means that there is no need to test for HbsAb in our case.

Regarding the serologic test for anti-Syphilis antibodies, there are two distinct categories that are divided according to the type of antigen that the antibodies are directed against. Antibodies to proteins from *T. pallidum* are found by treponemal assays. Antibodies against lipoidal antigens, harmed host cells, and perhaps treponemes are found by non-treponemal testing. To confirm the infection and establish whether the disease is active, both tests are performed. It would have been beneficial to use additional specialized Treponemal tests, all of which are unavailable in Ethiopia. These tests include the fluorescent treponemal antibody absorbed (FTA-ABS) test, chemoluminescence immunoassays, and enzyme immunoassays that detect treponemal antibodies.⁶

In general, we accepted some of the writers' ideas where there is no constraint on advanced laboratory tests. However, it cannot nullify the benefit of other testing (HBsAg test, anti-HCV test, and anti-syphilis test).

Disclosure

The authors report no conflicts of interest in this communication.

References

1. The European initiative hepatitis C and drug use. Available from: <https://www.hcvcommunitytesting.info/hepatitis-b-serology/>. Accessed December 21, 2022.
2. Centres for Diseases control and prevention (CDC). Viral hepatitis (Hepatitis B virus): interpretation of hepatitis B serologic test results-table. Available from: <https://www.cdc.gov/hepatitis/hbv/testingchronic.htm>. Accessed December 21, 2022.
3. Centres for Diseases control and prevention (CDC). Viral hepatitis (Hepatitis C virus): recommended testing sequence for identifying current hepatitis C Virus (HCV) infection. Available from: <https://www.cdc.gov/hepatitis/hcv/guidelinesc.htm>. Accessed December 21, 2022.
4. Joshi SN. Hepatitis C screening. *Ochsner J.* 2014;14(4):664–668. PMID: 25598732; PMCID: PMC4295744.
5. Ayalew G, Assefa A, Amsalu A, et al. Immune protection of Hepatitis B vaccine among children living in Gondar town, Northwest Ethiopia, 2017. *Ethiop Med J.* 2019;2019:5.
6. Henao-Martínez AF, Johnson SC. Diagnostic tests for syphilis: new tests and new algorithms. *Neurol Clin Pract.* 2014;4(2):114–122. PMID: 27606153; PMCID: PMC4999316. doi:10.1212/01.CPJ.0000435752.17621.48

Dove Medical Press encourages responsible, free and frank academic debate. The content of the Infection and Drug Resistance 'letters to the editor' section does not necessarily represent the views of Dove Medical Press, its officers, agents, employees, related entities or the Infection and Drug Resistance editors. While all reasonable steps have been taken to confirm the content of each letter, Dove Medical Press accepts no liability in respect of the content of any letter, nor is it responsible for the content and accuracy of any letter to the editor.

Infection and Drug Resistance

Dovepress

Publish your work in this journal

Infection and Drug Resistance is an international, peer-reviewed open-access journal that focuses on the optimal treatment of infection (bacterial, fungal and viral) and the development and institution of preventive strategies to minimize the development and spread of resistance. The journal is specifically concerned with the epidemiology of antibiotic resistance and the mechanisms of resistance development and diffusion in both hospitals and the community. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/infection-and-drug-resistance-journal>

<https://doi.org/10.2147/IDR.S401620>